An anti-inflammatory or anti-aging composition containing extracellular vesicles derived from plants, fungi, or microalgae.

CN123124883APending Publication Date: 2026-11-17THE UNIV OF TOKYO
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202480088505.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-12-22
Filing Date
2024-12-23
Publication Date
2026-11-17

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

An anti-inflammatory or anti-aging composition comprising extracellular vesicles derived from plants, fungi, or microalgae of the following families: Apiaceae, Lamiaceae, Theaceae, Selaginellaceae, Brassicaceae, Asteraceae, Amaranthaceae, Amaryllidaceae, Fabaceae, Cucurbitaceae, Zingiberaceae, Polygonaceae, Dioscoreaceae, Vitaceae, Rosaceae, Solanaceae, Ericaceae, Lythraceae, or Rutaceae.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to an anti-inflammatory or anti-aging composition containing extracellular vesicles derived from plants, mushrooms, or microalgae. Background Technology

[0002] Extracellular vesicles (EVs) are a collective term for vesicles secreted by the cells of various organisms, including animals and plants, and surrounded by a lipid bilayer. They include exosomes derived from the endosome membrane. EVs store proteins, lipids, and nucleic acids.

[0003] In addition, EVs are known to have various physiological activities (see Patent Documents 1-5).

[0004] Existing technical documents Patent documents Patent Document 1: Japanese Patent Publication No. 2018-531932 Patent Document 2: Japanese Patent Publication No. 2020-535189 Patent Document 3: Japanese Patent Publication No. 2021-193070 Patent Document 4: Japanese Patent Publication No. 2022-525131 Patent Document 5: Japanese Patent Publication No. 2022-543061 The technical problem to be solved by the present invention is to provide a new composition that can inhibit inflammation or aging. Summary of the Invention

[0005] Solution to the technical problem The inventors of this application conducted in-depth research to solve the above-mentioned technical problems and found that extracellular vesicles derived from specific plants, fungi, or microalgae have a strong inhibitory effect on inflammation or aging, thus completing this invention.

[0006] That is, the present invention is as follows. [1] An anti-inflammatory or anti-aging composition comprising extracellular vesicles derived from plants, fungi, or microalgae of the families Apiaceae, Lamiaceae, Theaceae, Selaginellaceae, Brassicaceae, Asteraceae, Amaranthaceae, Amaryllidaceae, Fabaceae, Cucurbitaceae, Zingiberaceae, Polygonaceae, Dioscoreaceae, Vitaceae, Rosaceae, Solanaceae, Ericaceae, Lythraceae, or Rutaceae. [2] An anti-inflammatory or anti-aging composition comprising, derived from parsley, Ashitaba, clover, Violet Harmony, carrot, carrot tops, fruit carrot, coriander, dill, fennel, rosemary, spearmint, lemon balm, perilla, marjoram, sweet basil, thyme, oregano, mint, sage, tea tree, camellia, Selaginella lepidophylla, Brussels sprouts, Cauliflore (stick cauliflower), Romanesco broccoli, arugula, horseradish, Komatsuna, wasabi, cauliflower, red radish, and Rucola selvatica (wild rocket, diplotaxis). Tenuifolia (Japanese: セルバチィコ), Chinese cabbage (Brassica rapa chinensis), broccoli, mizuna, radish, white radish, watercress, turnip, tatsoi, artichoke, red amaranth, garland chrysanthemum, lettuce (Lactuca sativa, Korean lettuce, Japanese: サンチュ), burdock, endive, Jerusalem artichoke, romaine lettuce, red chicory.Radicchio, Dysphania ambrosioides (epazote), Amaranth, Spinach, Swiss chard, Beetroot, Salsola komarovii, Allium tuberosum, Allium ampeloprasum, Onion, Shallot (English: shallot, French: Échalote), Moroccan beans, Edamame, Winged beans, Snow peas, Snap peas, Pea sprouts, Watermelon, Zucchini, Loofah, Ginger, Zingiber mioga, Rhubarb, Yam, Muscat grapes, Mulberry, Paprika, Chili peppers, Potatoes, Green peppers, Blueberries, Pomegranate, Citrus hystrix (kaffir lime), Kumquat, Agaricus galanga *Bisporus* (Japanese: マッシュルーム), an extracellular vesicle of *Hypsizygus tessulatus*, or *Euglena*. [3] The compositions described in [1] or [2] inhibit the expression of inflammatory cytokines or aging markers. [4] The composition as described in [3], wherein the inflammatory cytokines or aging markers are IL-4, IL-6, IL-13, IL-33, IL-1β, CXCL1, CXCL2, TNF-α, p15 or p16. [5] The composition of any one of [1] to [4] is used in food, cosmetics or pharmaceuticals.

[0012] The present invention includes the following embodiments.

[0013] [A1] A method for inhibiting inflammation or aging that uses extracellular vesicles from plants, fungi, or microalgae derived from the families Apiaceae, Lamiaceae, Theaceae, Selaginellaceae, Brassicaceae, Asteraceae, Amaranthaceae, Amaryllidaceae, Fabaceae, Cucurbitaceae, Zingiberaceae, Polygonaceae, Dioscoreaceae, Vitaceae, Rosaceae, Solanaceae, Ericaceae, Lythraceae, or Rutaceae.

[0014] [A2] A method to suppress inflammation or aging that uses ingredients derived from parsley, ashtray, clover, purple carrot, carrot, carrot tops, fruit carrot, coriander, dill, fennel, rosemary, spearmint, lemon balm, perilla, marjoram, sweet basil, thyme, oregano, mint, sage, tea tree, camellia, selaginella, Brussels sprouts, Japanese cauliflower, Romanesco broccoli, arugula, horseradish, komatsuna, wasabi, cauliflower, red radish, thin-leaf mustard, bok choy, broccoli, mizuna, radish, white radish, watercress, and other herbs. Turnip, tatsoi, artichoke, red amaranth, garland chrysanthemum, lettuce, burdock, chicory, Jerusalem artichoke, romaine lettuce, red chicory, wild mustard, amaranth, spinach, Swiss chard, beetroot, wingless hogweed, leek, leek, onion, scallion, Moroccan green bean, edamame, winged bean, snow pea, sweet bean, pea sprout, watermelon, zucchini, loofah, ginger, ginger, rhubarb, yam, muscat grape, mulberry, bell pepper, chili pepper, potato, green pepper, blueberry, pomegranate, Thai lemon, kumquat, button mushroom, shiitake mushroom, crab mushroom, or extracellular vesicles of Euglena.

[0015] [B1] The use of extracellular vesicles in inhibiting inflammation or aging, wherein the extracellular vesicles are derived from plants, fungi or microalgae of the Apiaceae, Lamiaceae, Theaceae, Selaginellaceae, Brassicaceae, Asteraceae, Amaranthaceae, Amaryllidaceae, Fabaceae, Cucurbitaceae, Zingiberaceae, Polygonaceae, Dioscoreaceae, Vitaceae, Rosaceae, Solanaceae, Ericaceae, Lythraceae or Rutaceae families.

[0016] [B2] Use of extracellular vesicles in inhibiting inflammation or aging, said extracellular vesicles are derived from parsley, Ashitaba, clover, purple carrot, carrot, carrot top, fruit carrot, coriander, dill, fennel, rosemary, spearmint, lemon balm, perilla, marjoram, sweet basil, thyme, oregano, mint, sage, tea tree, camellia, selaginella, Brussels sprouts, Japanese cauliflower, Romanesco broccoli, arugula, horseradish, komatsuna, wasabi, cauliflower, red radish, thin-leaf mustard, bok choy, broccoli, mizuna, radish, white radish, etc. Radish, watercress, turnip, tatsoi, artichoke, red amaranth, garland chrysanthemum, lettuce, burdock, chicory, Jerusalem artichoke, romaine lettuce, red chicory, purslane, amaranth, spinach, Swiss chard, beetroot, wingless hogweed, leek, scallion, onion, green onion, Moroccan green bean, edamame, winged bean, snow pea, sweet bean, pea sprouts, watermelon, zucchini, loofah, ginger, ginger, rhubarb, yam, muscat grape, mulberry, bell pepper, chili pepper, potato, green bell pepper, blueberry, pomegranate, Thai lemon, kumquat, button mushroom, shiitake mushroom, enoki mushroom, or euglena.

[0017] [C1] The use of extracellular vesicles in the manufacture of compositions that inhibit inflammation or aging, wherein the extracellular vesicles are derived from plants, fungi, or microalgae of the Apiaceae, Lamiaceae, Theaceae, Selaginellaceae, Brassicaceae, Asteraceae, Amaranthaceae, Amaryllidaceae, Fabaceae, Cucurbitaceae, Zingiberaceae, Polygonaceae, Dioscoreaceae, Vitaceae, Rosaceae, Solanaceae, Ericaceae, Lythraceae, or Rutaceae families.

[0018] [C2] Use of extracellular vesicles in the manufacture of compositions that inhibit inflammation or aging, said extracellular vesicles being derived from parsley, Ashitaba, clover, purple carrot, carrot, carrot tops, fruit carrot, coriander, dill, fennel, rosemary, spearmint, lemon balm, perilla, marjoram, sweet basil, thyme, oregano, mint, sage, tea tree, camellia, selaginella, Brussels sprouts, Japanese cauliflower, Romanesco broccoli, arugula, horseradish, komatsuna, wasabi, cauliflower, red radish, thin-leaf mustard, bok choy, broccoli, mizuna, and small radish. Radish, white radish, watercress, turnip, tatsoi, artichoke, red amaranth, garland chrysanthemum, lettuce, burdock, chicory, Jerusalem artichoke, romaine lettuce, red chicory, purslane, amaranth, spinach, Swiss chard, beetroot, wingless hogweed, leek, scallion, onion, green onion, Moroccan green bean, edamame, winged bean, snow pea, sweet pea, pea sprouts, watermelon, zucchini, loofah, ginger, ginger, rhubarb, yam, muscat grape, mulberry, bell pepper, chili pepper, potato, green bell pepper, blueberry, pomegranate, Thai lemon, kumquat, button mushroom, shiitake mushroom, crab mushroom, or euglena.

[0019] [D1] Extracellular vesicles used to suppress inflammation or aging are derived from plants, fungi, or microalgae belonging to the Apiaceae, Lamiaceae, Theaceae, Selaginellaceae, Brassicaceae, Asteraceae, Amaranthaceae, Amaryllidaceae, Fabaceae, Cucurbitaceae, Zingiberaceae, Polygonaceae, Dioscoreaceae, Vitaceae, Rosaceae, Solanaceae, Ericaceae, Lythraceae, or Rutaceae families.

[0020] [D2] Extracellular vesicles used to suppress inflammation or aging are derived from parsley, ashtray, clover, purple carrot, carrot, carrot tops, fruit carrot, coriander, dill, fennel, rosemary, spearmint, lemon balm, perilla, marjoram, sweet basil, thyme, oregano, mint, sage, tea tree, camellia, selaginella, Brussels sprouts, Japanese cauliflower, Romanesco broccoli, arugula, horseradish, komatsuna, wasabi, cauliflower, red radish, thin-leaf mustard, bok choy, broccoli, mizuna, radish, and white radish. Watercress, turnip, tatsoi, artichoke, red amaranth, garland chrysanthemum, lettuce, burdock, chicory, Jerusalem artichoke, romaine lettuce, red chicory, purslane, amaranth, spinach, Swiss chard, beetroot, wingless hogweed, leek, scallion, onion, green onion, Moroccan green bean, edamame, winged bean, snow pea, sweet pea, pea sprouts, watermelon, zucchini, loofah, ginger, ginger, rhubarb, yam, muscat grape, mulberry, bell pepper, chili pepper, potato, green bell pepper, blueberry, pomegranate, Thai lemon, kumquat, button mushroom, shiitake mushroom, crab mushroom, or euglena.

[0021] [E1] An anti-inflammatory preparation or aging inhibitor containing extracellular vesicles derived from plants, fungi, or microalgae of the Apiaceae, Lamiaceae, Theaceae, Selaginellaceae, Brassicaceae, Asteraceae, Amaranthaceae, Amaryllidaceae, Fabaceae, Cucurbitaceae, Zingiberaceae, Polygonaceae, Dioscoreaceae, Vitaceae, Rosaceae, Solanaceae, Ericaceae, Lythraceae, or Rutaceae families.

[0022] [E2] An anti-inflammatory preparation or aging inhibitor containing ingredients derived from parsley, ashtray, clover, purple carrot, carrot, carrot tops, fruit carrot, coriander, dill, fennel, rosemary, spearmint, lemon balm, perilla, marjoram, sweet basil, thyme, oregano, mint, sage, tea tree, camellia, selaginella, Brussels sprouts, Japanese cauliflower, Romanesco broccoli, arugula, horseradish, komatsuna, wasabi, cauliflower, red radish, thin-leaf mustard, bok choy, broccoli, mizuna, radish, white radish, watercress. Turnip, tatsoi, artichoke, red amaranth, garland chrysanthemum, lettuce, burdock, chicory, Jerusalem artichoke, romaine lettuce, red chicory, wild mustard, amaranth, spinach, Swiss chard, beetroot, wingless hogweed, leek, scallion, onion, green onion, Moroccan green bean, edamame, winged bean, snow pea, sweet bean, pea sprouts, watermelon, zucchini, loofah, ginger, ginger, rhubarb, yam, muscat grape, mulberry, bell pepper, chili pepper, potato, green bell pepper, blueberry, pomegranate, Thai lemon, kumquat, button mushroom, shiitake mushroom, crab mushroom, or extracellular vesicles of Euglena.

[0023] In each of the embodiments [A1] to [E2], It can inhibit the expression of inflammatory cytokines or aging markers. Inflammatory cytokines or aging markers may include IL-4, IL-6, IL-13, IL-33, IL-1β, CXCL1, CXCL2, TNF-α, p15, or p16. It can be used in food, cosmetics, or medicine.

[0024] The present invention includes the following embodiments. [6] An anti-inflammatory or anti-aging composition comprising extracellular vesicles derived from parsley or Euglena. [7] The anti-inflammatory or anti-aging effects of the compositions described in [6] are not diminished by thermal history. [8] The composition as described in [7] has a thermal process of heat treatment at or above 40°C.

[0028] In each of the embodiments [6] to [8], the composition may be heat-stable and may exhibit equivalent anti-inflammatory and / or anti-aging effects compared to the unheated composition, and may equally inhibit the expression of aging markers and cytokines compared to the unheated composition.

[0029] Invention Effects According to the present invention, it is possible to provide a composition containing novel extracellular vesicles capable of inhibiting inflammation or aging. Attached Figure Description

[0030] Figure 1 The image shows the fractions obtained from ultracentrifugation followed by sucrose density gradient ultracentrifugation in the preparation of EVs derived from parsley and ginger. The arrows indicate band 2 fractions.

[0031] Figure 2 shows the results of treating human IMR90 cells induced with cellular senescence by overexpression of activated Ras with EV fractions of plant, fungal, or microalgae solutions as described in Table 1, and measuring the expression levels of cellular senescence markers (IL6, p15, p16) by qRT-PCR. Additionally, the results of treating mouse macrophages (Raw-Blue cells) induced with LPS stimulation to show the expression levels of inflammatory cytokines (IL-6 or IL-1β). Figures 2-1 to 2-14 In 2-19 and 2-21, the upper part shows the results of the aging induction experiment with activated Ras overexpression, and the lower part shows the results of the inflammation induction experiment with LPS stimulation.

[0032] Figure 3-1The results show the expression of inflammatory cytokines (IL-6 or IL-1β) when EV fractions or EV samples derived from winged beans are obtained by ultracentrifugation or ultrafiltration through a sucrose density gradient, or when mouse macrophages (Raw-Blue cells) are sensitized with PBS and stimulated with LPS.

[0033] Figure 3-2 The results show the expression of inflammatory cytokines (IL-6 or IL-1β) when EVs derived from parsley or ginger ale obtained by ultrafiltration, or PBS-sensitized mouse macrophages (Raw-Blue cells) and stimulated with LPS.

[0034] Figure 4-1 A shows the results of nanoparticle tracking analysis of EV fractions derived from winged beans obtained by ultracentrifugation of sucrose density gradient.

[0035] Figure 4-1 B shows the results of nanoparticle tracking analysis of EVs samples derived from winged beans obtained by ultrafiltration.

[0036] Figure 4-2 A shows the results of nanoparticle tracking analysis of EV fractions derived from parsley obtained by sucrose density gradient ultracentrifugation.

[0037] Figure 4-2 B shows the results of nanoparticle tracking analysis of EVs derived from parsley obtained by ultrafiltration.

[0038] Figure 4-3 A shows the results of nanoparticle tracking analysis of EV fractions derived from ginger grosvenorii obtained by sucrose density gradient ultracentrifugation.

[0039] Figure 4-3 B shows the results of nanoparticle tracking analysis of EVs samples derived from ginger vineyards obtained by ultrafiltration.

[0040] Figure 4-4 The results of nanoparticle tracking analysis of EV fractions derived from Euglena are shown.

[0041] Figure 5-1 The results of analysis of facial skin condition (wrinkles, age spots, pores, skin texture) in a person after oral intake of parsley EVs using the VISIA skin imaging diagnostic device are shown.

[0042] Figure 5-2 The VISIA skin imaging diagnostic device was used to analyze the melanin accumulated in the deep layers of the skin of people who had taken parsley EVs orally.

[0043] Figure 6 A shows the results of expression of inflammatory cytokine (IL-6) in mouse macrophages (Raw-Blue cells) sensitized with ultrafiltration samples of parsley-derived EVs obtained without heating or after heating, and upon application of LPS stimulation.

[0044] Figure 6 B shows the results of expression of inflammatory cytokine (IL-6) in mouse macrophages (Raw-Blue cells) sensitized with ultrafiltration fractions of Euglena EVs obtained without heating or with heating, and then stimulated with LPS.

[0045] Figure 7A This study illustrates the changes in mouse body weight following oral administration of parsley EVs (PcELNs) at a dose of 1.0E+11 granules / day followed by ingestion of 3% DSS in drinking water to induce colitis. PBS was used as a control.

[0046] Figure 7B The mouse phenotypes after DSS ingestion are shown (Category 0: no phenotype, 1: diarrhea / bloody stool, 2: bleeding +, 3: bleeding ++, 4: bleeding +++, 5: anal bleeding).

[0047] Figure 7C The length of the large intestine (from directly below the cecum to the anus) at DSS intake is shown in the PBS group and the PcELNs group (Day 0: N=6, Day 3: N=3, Day 5: N=3, Day 7: N=6).

[0048] Figure 7D The results of RT-qPCT measurements (N=3) are shown. The large intestine from the cecum to the anus is divided into three segments: the proximal segment (anterior) is closer to the cecum, and the distal segment (posterior) is closer to the anus.

[0049] Figure 7E Images of HE, Alcian blue, and (β-CATENIN / ZO-1) immunostainings on days 0 and 7 of DSS treatment are shown (scale bar: 100 μm).

[0050] Figure 8 A shows the results of auricular thickness measured after soaking mice with TNCB-induced inflammation using EVs derived from Brussels sprouts, EVs derived from parsley, and PBS.

[0051] Figure 8 B shows the results of RT-qPCT assays to determine changes in the expression of inflammatory cytokines in the ear after immersion in a solution containing EVs following induced inflammation.

[0052] Figure 9 The average grip strength is shown. Mice were fed a high-fat diet and administered EVs derived from parsley and Brussels sprouts for 13 weeks. Grip strength was measured in each mouse using the Grip Strength Test.

[0053] Figure 10 The hanging time (the time a mouse can hold its position before falling from the metal mesh) and hanging score (the weight of each mouse multiplied by the hanging time) are shown. Mice were fed a high-fat diet and administered EVs derived from parsley and Brussels sprouts for 13 weeks. Mean muscle endurance was measured using the 4-limb Hanging Test.

[0054] Figure 11 The mean soleus muscle weight of mice was shown when they were fed a high-fat diet and given EVs derived from parsley and Brussels sprouts for 13 weeks. Detailed Implementation

[0055] The following describes in detail the methods for implementing the present invention (hereinafter referred to as "this embodiment"). It should be noted that the present invention is not limited to this embodiment.

[0056] The anti-inflammatory or anti-aging composition of this embodiment contains extracellular vesicles derived from plants, fungi, or microalgae of the Apiaceae, Lamiaceae, Theaceae, Selaginellaceae, Brassicaceae, Asteraceae, Amaranthaceae, Amaryllidaceae, Fabaceae, Cucurbitaceae, Zingiberaceae, Polygonaceae, Dioscoreaceae, Vitaceae, Rosaceae, Solanaceae, Ericaceae, Lythraceae, or Rutaceae families.

[0057] The extracellular vesicles contained in the anti-inflammatory or anti-aging compositions may contain extracellular vesicles derived from two or more different plants of the same family, or extracellular vesicles derived from two or more different fungi or microalgae. Additionally, the extracellular vesicles may contain extracellular vesicles derived from one or more different plants selected from the same family, or extracellular vesicles derived from one or more plants selected from a different family. They may contain extracellular vesicles derived from two or more different families. They may contain extracellular vesicles derived from plants and fungi, extracellular vesicles derived from plants and microalgae, extracellular vesicles derived from fungi and microalgae, or extracellular vesicles derived from plants, fungi, and microalgae.

[0058] The plants may be plants cultivated in open fields, or may be hydroponically cultivated plants. The fungi may be natural fungi, or may be fungi cultivated on artificial culture media or harvested logs. The microalgae may be cultured microalgae.

[0059] The extracellular vesicles of the present embodiment may be extracellular vesicles extracted by conventionally known methods using plants, fungi or microalgae as raw materials. In addition, the extracellular vesicles derived from plants, fungi or microalgae may be extracellular vesicles present in plants, fungi or microalgae extracted by conventionally known methods. Since plants, fungi or microalgae are used as raw materials, the extracellular vesicles may also contain solvents and reagents used in extraction, as well as components derived from plants, fungi or microalgae.

[0060] The plants of the Apiaceae family are not particularly limited, and examples thereof may be parsley, ashitaba, clover, violet carrot (Violet Harmony), carrot, carrot top (Japanese: You Ninjin), baby carrot, coriander, dill or fennel.

[0061] The plants of the Lamiaceae family are not particularly limited, and examples thereof may be rosemary, spearmint, lemon balm, perilla, marjoram, sweet basil, thyme, oregano, mint or sage. The perilla may be red perilla.

[0062] The plants of the Theaceae family are not particularly limited, and examples thereof may be tea plant and camellia.

[0063] The plants of the Selaginellaceae family are not particularly limited, and examples thereof may be Selaginella lepidophylla. Selaginella lepidophylla may also be referred to as resurrection plant or Rose of Jericho.

[0064] The plants of the Brassicaceae family are not particularly limited, and examples thereof may be brussels sprouts, Japanese cauliflower, romanesco broccoli, arugula, horseradish, komatsuna, wasabi, cauliflower, red core radish, rucola selvatica, brassica rapa chinensis, broccoli, mizuna, radish, daikon, watercress, turnip or tatsoi.

[0065] The plants of the Asteraceae family are not particularly limited, and examples thereof may be artichoke, Gynura bicolor, garland chrysanthemum, lettuce (Lactuca sativa), burdock, endive, Bodo Jerusalem artichoke, romaine lettuce or red chicory, radicchio.

[0066] There are no particular restrictions on plants in the Amaranthaceae family; for example, it can include dysphania ambrosioides (epazote), amaranth, spinach, Swiss chard, beets, or salsolakomarovii.

[0067] There are no particular restrictions on plants in the Amaryllidaceae family; for example, it can be chives (allium tuberosum), leeks (allium ampeloprasum), onions, or scallions (English: shallot, French: Échalote, Japanese: エシャロット).

[0068] There are no particular restrictions on legumes; for example, they can be Moroccan beans, edamame, winged beans, snow peas, snap peas, or pea sprouts.

[0069] There are no particular restrictions on plants in the Cucurbitaceae family; for example, it can be watermelon, zucchini, or loofah.

[0070] There are no particular restrictions on plants in the ginger family; for example, it can be ginger or ginger var. truncatum.

[0071] There are no particular restrictions on plants in the Polygonaceae family; for example, rhubarb can be used.

[0072] There are no particular restrictions on plants in the Dioscoreaceae family; for example, it can be yam.

[0073] There are no particular restrictions on the plants in the Vitaceae family; for example, it can be Muscat grapes.

[0074] There are no particular restrictions on plants in the Rosaceae family; for example, mulberry can be used.

[0075] There are no particular restrictions on plants in the Solanaceae family; for example, it can be bell pepper (paprika), chili pepper (togarashi), potato, or green bell pepper (peman).

[0076] There are no particular restrictions on plants in the Ericaceae family; for example, blueberries can be used.

[0077] There are no particular restrictions on plants in the Lythraceae family; for example, pomegranate can be used.

[0078] There are no particular restrictions on the plants in the Rutaceae family; for example, it can be Thai lemon (Citrus hystrix, Kaffirlime) or kumquat.

[0079] There are no particular restrictions on the type of fungus; for example, it can be button mushrooms, shiitake mushrooms, or enoki mushrooms. Fungi are also known as edible fungi.

[0080] There are no particular restrictions on the microalgae; for example, Euglena can be used.

[0081] This embodiment also provides an anti-inflammatory or anti-aging composition containing ingredients derived from parsley, ashtray, clover, purple carrot, carrot, carrot tops, fruit carrot, coriander, dill, fennel, rosemary, spearmint, lemon balm, perilla, marjoram, sweet basil, thyme, oregano, mint, sage, tea tree, camellia, selaginella, Brussels sprouts, Japanese cauliflower, Romanesco broccoli, arugula, horseradish, komatsuna, wasabi, cauliflower, red radish, thin-leaf mustard, bok choy, broccoli, mizuna, radish, and white radish. Watercress, turnip, tatsoi, artichoke, red amaranth, garland chrysanthemum, lettuce, burdock, chicory, Jerusalem artichoke, romaine lettuce, red chicory, purslane, amaranth, spinach, Swiss chard, beetroot, wingless hogweed, leek, leek, onion, scallion, Moroccan green bean, edamame, winged bean, snow pea, sweet bean, pea sprouts, watermelon, zucchini, loofah, ginger, ginger, rhubarb, yam, muscat grape, mulberry, bell pepper, chili pepper, potato, green pepper, blueberry, pomegranate, Thai lemon, kumquat, button mushroom, shiitake mushroom, crab mushroom, or extracellular vesicles of Euglena.

[0082] The extracellular vesicles used in this embodiment can be derived from extracellular vesicles of parsley, Euglena, Ashitaba, clover, purple carrot, carrot tops, rosemary, spearmint, lemon balm, perilla, marjoram, sweet basil, thyme, oregano, mint, tea tree, camellia, Selaginella tamariscina, Brussels sprouts, Japanese cauliflower, Romanesco broccoli, arugula, horseradish, Komatsuna, wasabi, cauliflower, red radish, thin-leaved mustard, artichoke, red amaranth, garland chrysanthemum, lettuce (Lactuca sativa), burdock, purslane, amaranth, Swiss chard, leek, onion, scallion, Moroccan green bean, edamame, winged bean, snow pea, watermelon, ginger, rhubarb, yam, muscat grape, mulberry, bell pepper, pomegranate, Thai lemon, or button mushroom. The extracellular vesicles used in this embodiment can be selected from any combination of the above-listed extracellular vesicles.

[0083] The anti-inflammatory or anti-aging composition in this embodiment has anti-inflammatory or anti-aging effects by containing extracellular vesicles as an active ingredient. It can possess anti-inflammatory or anti-aging effects by containing extracellular vesicles derived from parsley, Euglena, Ashitaba, clover, purple carrot, carrot tops, rosemary, spearmint, lemon balm, perilla, marjoram, sweet basil, thyme, oregano, mint, tea tree, camellia, Selaginella tamariscina, Brussels sprouts, Japanese cauliflower, Romanesco broccoli, arugula, horseradish, Komatsuna, wasabi, cauliflower, red radish, thin-leaved mustard, artichoke, red amaranth, garland chrysanthemum, lettuce, burdock, purslane, amaranth, Swiss chard, leek, onion, scallion, Moroccan green bean, edamame, winged bean, snow pea, watermelon, ginger, rhubarb, yam, muscat grape, mulberry, bell pepper, pomegranate, Thai lemon, or button mushroom as active ingredients. It can also possess anti-inflammatory or anti-aging effects by containing any combination of the above-mentioned extracellular vesicles as active ingredients.

[0084] As long as it can function as an active ingredient, the concentration of extracellular vesicles in anti-inflammatory or anti-aging compositions can be any amount, for example, 1.0 x 10⁻⁶. 5 1.0x10 6 1.0x10 7 1.0x10 8 1.0x10 9 Or 1.0x10 10 Particles / ml (or, particles / g) or more.

[0085] In this embodiment, extracellular vesicles (EVs) are a collective term for vesicles secreted by the cells of various organisms, such as animals and plants, and surrounded by a lipid bilayer. This includes exosomes derived from the endosome membrane. Additionally, in this specification, extracellular vesicles are also referred to as EVs, and EVs have the same meaning as extracellular vesicles.

[0086] In this embodiment, there are no particular limitations on the extracellular vesicles derived from plants, fungi, or microalgae. Those skilled in the art can obtain them by known methods, such as separation using ultracentrifugation, density gradient ultracentrifugation, ultrafiltration, chromatography, separation using microbeads or antibodies, polymer precipitation, or microfluidic separation techniques.

[0087] Specific examples of density gradient ultracentrifugation or ultrafiltration are shown below.

[0088] Density gradient ultracentrifugation Use a household juicer or similar device to extract juice from plants or fungi. Centrifuge the juice at 1,000–10,000 g for 10–60 minutes to remove larger fragments. Then, ultracentrifuge the supernatant at 120,000–150,000 g for 60 minutes to overnight to obtain a precipitate. Resuspend the precipitate in a buffer such as PBS, add it to a sucrose density gradient solution, and ultracentrifuge again at 120,000–150,000 g for 60 minutes to overnight. After ultracentrifugation, the target extracellular vesicles can be obtained by recovering the fractions accumulated at the 8–30% or 30–45% boundary (Band 1 or Band 2). Alternatively, depending on the situation, the recovered fractions can be mixed with a buffer such as PBS, followed by further ultracentrifugation, and the resulting precipitate can be used as the final extracellular vesicle sample.

[0089] Microalgae can be centrifuged at 1,000–3,000 g for 10–60 minutes, and the precipitate suspended in buffers such as PBS. The suspension can be directly or after freeze-thaw cycles using an ultrasonic homogenizer, followed by centrifugation at 1,000–10,000 g for 10–60 minutes to remove larger fragments. The supernatant obtained after ultracentrifugation at 120,000–150,000 g for 60 minutes to overnight yields the precipitate. This precipitate, suspended in buffers such as PBS, can be used directly as a sample for extracellular vesicles, or added to a sucrose density gradient solution and further ultracentrifuged at 120,000–150,000 g for 60 minutes to overnight. After ultracentrifugation, the target extracellular vesicles can be obtained by recovering the band 1 or band 2 fractions that accumulate at the 8-30% or 30-45% boundary. Alternatively, the recovered fractions can be mixed with buffers such as PBS and then ultracentrifuged again, and the resulting precipitate can be used as the final extracellular vesicle sample.

[0090] Ultrafiltration First, use a household juicer or similar device to extract juice from plants, fungi, or microalgae. Centrifuge the juice at 1,000–10,000 g for 10–60 minutes to remove larger fragments. Then, ultrafilter the supernatant using an ultrafiltration membrane, according to the size of the target extracellular vesicles, to obtain the target extracellular vesicles. Two or more ultrafiltration membranes may be used for filtration.

[0091] The extracellular vesicles derived from parsley or Euglena in the composition of this embodiment are extracellular vesicles obtained from parsley or Euglena, which can be obtained by density gradient ultracentrifugation or by ultrafiltration. Alternatively, extracellular vesicles obtained by a combination of both methods can be used.

[0092] Extracellular vesicles derived from parsley or Euglena can be extracellular vesicles obtained through the above treatment.

[0093] As shown in the embodiments, the extracellular vesicles derived from parsley or Euglena can be heat-resistant extracellular vesicles, and can also possess the characteristic that their anti-inflammatory or anti-aging effects are not diminished by thermal processes. The thermal processes can be above 35°C, above 40°C, above 50°C, above 55°C, above 60°C, above 65°C, above 70°C, above 75°C, above 80°C, above 85°C, above 90°C, or above 95°C, or below 140°C, below 130°C, below 120°C, below 110°C, or below 100°C. That is, the extracellular vesicles derived from parsley or Euglena in this embodiment can be thermally stable, for example, thermally stable at 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, or above 95°C. The temperature here is usually the external temperature, but can also be the internal temperature.

[0094] In this embodiment, the extracellular vesicles derived from parsley or Euglena are heat-resistant and resistant to sterilization treatments, and the anti-inflammatory or anti-aging effects of the extracellular vesicles are not weakened.

[0095] "No attenuation of effect" means, for example, that the measured data, when measured at appropriate temperature conditions (e.g., room temperature or the temperature described in the examples, or the temperature described in the operating procedure for measuring the effect), are not attenuated under specified heating conditions. For example, relative to the original measured data, this could be within ±20% or within 10%. Furthermore, heated extracellular vesicles derived from parsley or Euglena may be thermostable and may exhibit the same anti-inflammatory and / or anti-aging effects as unheated extracellular vesicles derived from parsley or Euglena, and may inhibit the expression of aging markers or cytokines as unheated extracellular vesicles derived from parsley or Euglena. Alternatively, compared to extracellular vesicles not derived from parsley or Euglena, the expression values ​​of aging markers or cytokines obtained by dividing the heated extracellular vesicles applied to cells by the expression values ​​of unheated extracellular vesicles applied to cells may be smaller. The anti-inflammatory or anti-aging compositions in this embodiment, when containing heat-stable extracellular vesicles derived from parsley or Euglena, can be easily heat-sterilized without losing their activity, for example, before commercialization.

[0096] The size of extracellular vesicles obtained from plants, fungi, or microalgae can be analyzed using methods known to those skilled in the art, such as nanoparticle tracking analysis (NTA) to study the particle size, particle size distribution, and concentration of extracellular vesicles.

[0097] Extracellular vesicles obtained using density gradient ultracentrifugation can have particle sizes ranging from 10 to 500 nm, with a higher concentration in the 50 to 450 nm particle size range. Conversely, extracellular vesicles obtained using ultrafiltration can have particle sizes ranging from 10 to 300 nm, with a higher concentration in the 50 to 250 nm particle size range. Compared to density gradient ultracentrifugation, ultrafiltration can yield extracellular vesicles with a narrower particle size range.

[0098] In this embodiment, "anti-inflammatory" refers to, for example, the effect of inhibiting inflammation, the effect of preventing the further development of inflammation, or the effect of preventing inflammation.

[0099] The "anti-inflammatory effect" of the composition in this embodiment can be achieved, for example, by inhibiting the expression of inflammatory cytokines (IL-4, IL-6, IL-13, IL-33, IL-1β, CXCL1, CXCL2, or TNF-α, etc.) in cells, thereby inhibiting the release of cytokines to exert an anti-inflammatory effect.

[0100] In addition, for example, it can relieve swelling, pain, and fever caused by inflammation through its anti-inflammatory effects, and can also inhibit inflammation without accompanying symptoms such as swelling.

[0101] The composition of this embodiment is applicable to the treatment and prevention of various inflammations. Inflammation can be acute or chronic, and may also be caused by allergic or autoimmune diseases. Furthermore, the composition of this embodiment can be applied to inflammatory diseases such as dermatitis, bronchitis, arthritis, gastritis, hepatitis, nephritis, encephalitis, systemic lupus erythematosus, ulcerative colitis, Crohn's disease, and dry eye syndrome; as well as inflammation-related diseases such as diabetes, renal insufficiency, hepatic insufficiency, cardiovascular disease, arteriosclerosis, cerebral infarction, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, narcolepsy, or cancer; and to the treatment or prevention of decreased immunity, muscle strength / endurance decline, sarcopenia (which may be age-related sarcopenia), frailty, osteoporosis, joint diseases such as knee osteoarthritis, spinal deformities, tendon degeneration, weight loss, skin pigmentation, wrinkles, and presbyopia. Moreover, the composition of this embodiment can also be applied to the treatment of COVID-19 infectious diseases or their sequelae, or other infectious diseases.

[0102] The composition of this embodiment can exert its anti-inflammatory effect by being applied directly or indirectly to the affected area.

[0103] Furthermore, the composition of this embodiment can also inhibit inflammation-related aging by suppressing inflammation. That is, the composition of this embodiment has an anti-aging effect; in this embodiment, while having an anti-inflammatory effect, it can also be said to have an anti-aging effect. Additionally, anti-aging refers to suppressing aging or symptoms associated with aging.

[0104] The relationship between inflammation and aging is as follows.

[0105] Cellular senescence, which plays an important role in individual aging (Baker et al., Nature 479:232-236 2011.), is considered a chronic inflammatory state. Furthermore, senescent cells show increased expression of cellular senescence markers such as p16, p15, and p21, and secrete inflammatory cytokines (e.g., IL-6, IL-8), thus demonstrating an association between inflammation and the development of age-related diseases (Birch et al., Genes Dev. 34:1565-1576 2020., Sharpless et al., Nat. Rev. Cancer 15:397-408 2015., and van Deursen, Nature 509:439-446 2014.).

[0106] In this embodiment, "aging inhibition" refers to the effect of inhibiting aging, preventing aging, etc. "Aging inhibition" can be used interchangeably with "anti-aging." The "aging inhibition effect" achieved by the composition of this embodiment can inhibit, for example, symptoms related to cellular aging. It can inhibit aging-related symptoms of epithelial cells, bone cells, cartilage cells, nerve cells, muscle cells, fat cells, hepatocytes, and lymphocytes, such as wrinkles, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, narcolepsy, muscle strength / endurance decline, sarcopenia, frailty, osteoporosis, joint diseases such as knee osteoarthritis, spinal deformities, tendon degeneration, weight loss, diabetes, decreased immunity, decreased kidney function, decreased liver function, cardiovascular diseases, arteriosclerosis, cerebral infarction, and cancer. Furthermore, it can also inhibit symptoms caused by novel coronavirus infectious diseases or their sequelae, or other infectious diseases. Additionally, it can also result in a lifespan extension effect.

[0107] In the "anti-aging effect," for example, the anti-aging effect is achieved by inhibiting the expression of aging markers (p15, p16, IL-6) or cytokines (IL-4, IL-6, IL-13, IL-33, IL-1β, CXCL1, CXCL2, or TNF-α, etc.) in cells, thereby inhibiting the release of cytokines. That is, the composition of this embodiment can inhibit the expression of aging markers (IL-6, p15, or p16, etc.) or cytokines (IL-4, IL-6, IL-13, IL-33, IL-1β, CXCL1, CXCL2, or TNF-α, etc.) in cells and inhibit the release of cytokines.

[0108] The composition of this embodiment can exert anti-inflammatory or anti-aging effects by being applied directly or indirectly to the affected area.

[0109] For example, when the expression level of cytokines is suppressed to 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, or 10% or less compared to the composition of this embodiment without addition or application, it can be judged that it has anti-inflammatory or anti-aging effects. Preferably, when the expression level of cytokines is suppressed to 70% or less in aging induction experiments (p15, p16, IL-6) and to 40% or less in inflammation induction experiments (IL-6, IL-1β) compared to the composition of this embodiment without addition or application, it can be judged that it has anti-aging or anti-inflammatory effects.

[0110] The anti-inflammatory composition of this embodiment can simultaneously possess both anti-inflammatory and anti-aging effects. Furthermore, the anti-aging composition of this embodiment can simultaneously possess both anti-inflammatory and anti-aging effects. That is, the anti-inflammatory composition can be an anti-aging composition, or vice versa.

[0111] The anti-inflammatory or anti-aging composition of this embodiment can have skin-improving effects. For example, by applying the anti-inflammatory or anti-aging composition, it can promote whitening or skin renewal, or improve pores, pigmentation (age spots, melasma, inflammatory pigmentation), latent pigmentation (invisible precursors to pigmentation), redness, dullness, rough skin texture, firmness, and sagging. These effects can be evaluated using known methods, such as using an image diagnostic device.

[0112] The composition of this embodiment can be used in food, cosmetics, or pharmaceuticals. Specifically, this embodiment also provides an anti-inflammatory or anti-aging composition for use in food, cosmetics, or pharmaceuticals.

[0113] The composition can be in a form suitable for use in food, cosmetics, or pharmaceuticals, and is not particularly limited thereto. For example, it can be in a form suitable for use, such as solid, liquid, granules, powder, capsule, paste, or gel. Furthermore, when forming capsules, for example, one or more layers of film can be applied as needed. To form these forms, existing and known additives can be used, and are not particularly limited thereto. For example, excipients, binders, diluents, disintegrants, buffers, thickeners, stabilizers, emulsifiers, dispersants, suspending agents, preservatives, etc., known to those skilled in the art, can be used as needed.

[0114] There are no particular limitations on the composition used in food, and examples include beverages and foods, health foods, functional foods, foods for specific health purposes, nutritional functional foods, health supplements and nutritional supplements.

[0115] There are no particular limitations on the composition used in cosmetics, and examples include scalp cosmetics, skin cosmetics, setting cosmetics, perfumes, nail cosmetics, bath cosmetics, etc.

[0116] The dosage form of a composition used in a pharmaceutical product is not particularly limited, and examples include oral preparations (tablets, capsules, granules, fine granules, powders, liquids, syrups, chewable tablets, lozenges, etc.), ointments, gels, creams, injections, sublingual preparations, inhalers, suppositories, liniments, patches, and eye / nasal drops. The above dosage forms can also be used for food or cosmetic compositions.

[0117] The composition may be provided with instructions such as "inhibit inflammation", "for people concerned about aging", "prevent muscle loss", "inhibit muscle weakness", "increase muscle mass", "strengthen muscle strength", "improve muscle endurance" and "promote skin renewal".

[0118] Preferably, the composition may contain any amount of extracellular vesicles, as long as they can exert anti-inflammatory or anti-aging effects. Additionally, other active ingredients may be included, provided they do not impair these effects.

[0119] The anti-inflammatory or anti-aging composition of this embodiment is also applicable to other embodiments described below.

[0120] As another implementation method, a method for inhibiting inflammation or aging is provided, which utilizes extracellular vesicles from plants, fungi, or microalgae derived from the families Apiaceae, Lamiaceae, Theaceae, Selaginellaceae, Brassicaceae, Asteraceae, Amaranthaceae, Amaryllidaceae, Fabaceae, Cucurbitaceae, Zingiberaceae, Polygonaceae, Dioscoreaceae, Vitaceae, Rosaceae, Solanaceae, Ericaceae, Lythraceae, or Rutaceae. In addition, as another implementation method, a method for inhibiting inflammation or aging is provided, which utilizes ingredients derived from parsley, ashtray, clover, purple carrot, carrot, carrot tops, fruit carrot, coriander, dill, fennel, rosemary, spearmint, lemon balm, perilla, marjoram, sweet basil, thyme, oregano, mint, sage, tea tree, camellia, selaginella, Brussels sprouts, Japanese cauliflower, Romanesco broccoli, arugula, horseradish, komatsuna, wasabi, cauliflower, red radish, thin-leaf mustard, bok choy, broccoli, mizuna, and radishes. White radish, watercress, turnip, tatsoi, artichoke, red amaranth, garland chrysanthemum, lettuce, burdock, chicory, Jerusalem artichoke, romaine lettuce, red chicory, purslane, amaranth, spinach, Swiss chard, beetroot, wingless hogweed, leek, scallion, onion, green onion, Moroccan green bean, edamame, winged bean, snow pea, sweet pea, pea sprouts, watermelon, zucchini, loofah, ginger, ginger, rhubarb, yam, muscat grape, mulberry, bell pepper, chili pepper, potato, green bell pepper, blueberry, pomegranate, Thai lemon, kumquat, button mushroom, shiitake mushroom, enoki mushroom, or extracellular vesicles of Euglena. Methods for inhibiting inflammation or aging are implemented, for example, to inhibit inflammation or aging outside or inside the human body. In addition, inflammation or aging outside or inside the human body can be inhibited by implementing them in situations where it is necessary to inhibit inflammation or aging or in the treatment of diseases caused by inflammation or aging.

[0121] As another implementation, an anti-inflammatory agent or aging inhibitor is also provided, which contains extracellular vesicles derived from plants, fungi, or microalgae of the Apiaceae, Lamiaceae, Theaceae, Selaginellaceae, Brassicaceae, Asteraceae, Amaranthaceae, Amaryllidaceae, Fabaceae, Cucurbitaceae, Zingiberaceae, Polygonaceae, Dioscoreaceae, Vitaceae, Rosaceae, Solanaceae, Ericaceae, Lythraceae, or Rutaceae families.

[0122] Additionally, as another implementation method, an anti-inflammatory agent or aging inhibitor is provided, containing ingredients derived from parsley, ashtray, clover, purple carrot, carrot, carrot tops, fruit carrot, coriander, dill, fennel, rosemary, spearmint, lemon balm, perilla, marjoram, sweet basil, thyme, oregano, mint, sage, tea tree, camellia, selaginella, Brussels sprouts, Japanese cauliflower, Romanesco broccoli, arugula, horseradish, komatsuna, wasabi, cauliflower, red radish, thin-leaf mustard, bok choy, broccoli, mizuna, and radish. White radish, watercress, turnip, tatsoi, artichoke, red amaranth, garland chrysanthemum, lettuce, burdock, chicory, Jerusalem artichoke, romaine lettuce, red chicory, purslane, amaranth, spinach, Swiss chard, beetroot, wingless hogweed, leek, scallion, onion, green onion, Moroccan green bean, edamame, winged bean, snow pea, sweet bean, pea sprouts, watermelon, zucchini, loofah, ginger, ginger, rhubarb, yam, muscat grape, mulberry, bell pepper, chili pepper, potato, green bell pepper, blueberry, pomegranate, Thai lemon, kumquat, button mushroom, shiitake mushroom, enoki mushroom, or extracellular vesicles of Euglena.

[0123] There are no particular restrictions on anti-inflammatory agents or aging inhibitors; they can be, for example, oral formulations (tablets, capsules, granules, fine granules, powders, liquids, syrups, chewable tablets, lozenges, etc.), ointments, gels, creams, injections, sublingual preparations, inhalants, and suppositories. To form these dosage forms, existing and known additives can be used without particular limitation; excipients, binders, diluents, disintegrants, buffers, thickeners, stabilizers, emulsifiers, dispersants, suspending agents, and preservatives, etc., known in the industry, can be used as needed. Additionally, anti-inflammatory agents or aging inhibitors can be incorporated into food, cosmetics, or pharmaceuticals for provision.

[0124] Compositions containing anti-inflammatory agents can be anti-inflammatory compositions, and compositions containing aging inhibitors can be anti-aging compositions. Anti-inflammatory compositions or anti-aging compositions containing anti-inflammatory agents or aging inhibitors can be used in food, cosmetics, or pharmaceuticals.

[0125] The anti-inflammatory or anti-aging composition, or anti-inflammatory agent or anti-aging inhibitor of this embodiment, is typically administered to animals, including humans. The dosage or frequency of administration is appropriately set according to the route of administration and various conditions of the subject, such as age, weight, and symptoms. The subject is preferably a mammal, more preferably a human, monkey, cat, pig, horse, cattle, mouse, rat, guinea pig, dog, or rabbit, and even more preferably a human.

[0126] Methods for inhibiting inflammation or aging may include administering an anti-inflammatory or anti-aging composition, or an anti-inflammatory agent or an anti-aging inhibitor, to a subject.

[0127] In this specification, methods include treatment methods and non-treatment methods; in addition, uses include therapeutic uses and non-therapeutic uses.

[0128] [Example] The present invention will be further illustrated below with specific examples. However, the present invention is not limited thereto.

[0129] <Example 1> (1) Evaluation of the anti-aging and anti-inflammatory effects of EVs in human IMR90 cells and mouse macrophages (1-1) Culture of normal human fibroblasts IMR90 cells Human normal fibroblast IMR90 cells were cultured in E-MEM medium (WAKO) supplemented with 10% FBS, MEM NEAA (gibco), and sodium pyruvate (gibco) at 37°C, 3% O2, and 5% CO2, at a growth rate of 5 × 10⁻⁶ cells / year. 5 Subculture at a ratio of 1 cell per 100 mm culture dish.

[0130] (1-2) Establishment of IMR90 cells with cancer-type Ras induction ability The plasmid pLNCX2 ER:ras (AddGene) was introduced into retroviral packaging cells Plat-A using polyethyleneimine and cultured for one week. This generated a retrovirus containing the ER:ras gene in the culture supernatant of Plat-A. The ER:ras gene was then introduced into IMR90 cells by adding hexadimethrine bromide (Merck) to the culture supernatant containing this retrovirus and adding it to the culture medium for IMR90 cells. Furthermore, by adding G418 (gibco) to the IMR90 cell culture medium to select only IMR90 cells infused with the ER:ras gene, an IMR90 cell line capable of inducing cellular senescence via the Ras gene was established.

[0131] (1-3) Culture of mouse macrophages Mouse macrophages (Raw-Blue cells, manufactured by InvivoGen) were cultured in Dulbecco's modified eagle medium (DMEM) (Thermo Fisher) supplemented with 10% FBS, 100 μg / ml Normocin (InvivoGen), and Pen-Strep (100 U / ml) at 37°C and 5% CO2, at a growth rate of 4.7 × 10⁻⁶ cells / mL. 6 Subculture at a ratio of 1 cell per 100 mm culture dish.

[0132] (1-4) Preparation of EVs by ultracentrifugation using sucrose density gradient EV fractions derived from the plants and fungi listed in Table 1 were prepared. First, the plants and fungi were washed with water in a plastic container, drained, and then juiced using a household juicer (HUROM). The juice was centrifuged at 3,000 g for 20 minutes using an Avati JE (JA-14 rotor, Bechman Courlter) and then twice at 10,000 g for 40 minutes to remove larger fragments. Next, the supernatant was ultracentrifuged at 150,000 g for 90 minutes using an Optima XE-90 (SW32 Ti rotor, Bechman Courlter) to obtain a precipitate. This precipitate contained EVs. After suspending the precipitate in PBS, it was added to a sucrose density gradient solution (8%, 30%, 45%, 60%) and further ultracentrifuged at 150,000 g for 90 minutes. After ultracentrifugation, the Band 2 fraction accumulated at the 30-45% boundary was recovered using a 20 mL syringe (TERUMO brand). The fraction was mixed into PBS and then ultracentrifuged at 150,000 g for 90 minutes. The precipitate was resuspended in PBS to obtain the EV fraction solution. The fractions of parsley and ginger after adding sucrose gradient solution and ultracentrifugation are shown below. Figure 1 The arrow indicates the Band 2 fraction. The Band 2 fractions of parsley and ginger have a density of less than 1.18 g / ml.

[0133] Microalgae were recovered by centrifugation at 3,000g for 20 minutes, suspended in PBS, and then sonicated using an ultrasonic homogenizer (SONYFIER BRANSON). The homogenate was centrifuged at 3,000g for 20 minutes, followed by two further centrifugations at 10,000g for 40 minutes each to remove larger fragments. The supernatant was then ultracentrifuged at 150,000g for 90 minutes to obtain a precipitate. This precipitate contained EVs, so it was suspended in PBS for use, or added to a sucrose density gradient solution (8%, 30%, 45%, 60%) and ultracentrifuged at 150,000g for 90 minutes. After ultracentrifugation, the Band 2 fraction accumulated at the 30-45% boundary was recovered using a 20mL syringe (TERUMO), mixed with PBS, and ultracentrifuged at 150,000g for 90 minutes. The precipitate was then suspended in PBS to obtain the EV fraction solution.

[0134] Table 1 (1-5) Preparation of EVs samples using ultrafiltration membrane Winged beans, parsley, and ginger were washed in a plastic container, drained, and juiced using a household juicer (HUROM). The juice was centrifuged at 3,000g for 20 minutes using an Avati JE (JA-14 rotor, Bechman Courlter) and then further centrifuged at 20,000g for 40 minutes to remove larger pieces. The resulting supernatant was passed through a Supracap depth capsule filter (Cytiva) and then ultrafiltered using a TFF Omega membrane (Cytiva) to obtain the EVs sample.

[0135] (1-6) LPS stimulation treatment The concentration of EVs prepared using ultracentrifugation with sucrose density gradient or ultrafiltration membrane was 1.0 × 10⁻⁶. 10 EV fractional solutions or EV samples with particle / ml were prepared at 0.8 × 10⁻⁶. 5 Sixteen hours after sensitizing mouse macrophages with cell / well seeding in 12-well culture dishes, the cells were washed with PBS and stimulated for 24 hours with 1 μg / ml LPS (Salmonella Minnesota R595, manufactured by WAKO) to induce inflammation. Following stimulation, the cells were washed with PBS, and RNA was extracted from the mouse macrophages using TRIsure (Nippon Genetics).

[0136] Evaluation of the effects of EVs on the expression of aging markers in Ras-induced aging human IMR90 cells and the expression of inflammatory cytokines in mouse macrophages stimulated by LPS. 24 hours before adding the EV fraction solution or EV sample, at a concentration of 4~6×10 4 Cells / well: IMR90 cells were seeded into 12-well culture dishes.

[0137] EV fractions or EV samples prepared by sucrose density gradient ultracentrifugation or ultrafiltration were subjected to a 1×10⁻⁶ ppm filtration. 10 Particles / ml were added to IMR90 cells. Simultaneously, 4-hydroxytamoxifen was added to IMR90 cells to overexpress activated Ras and induce cellular senescence. RNA was then extracted from IMR90 cells, and the expression levels of cellular senescence markers (p15, p16, Il6) were measured by RT-qPCR to evaluate the senescence-inhibiting effect of EVs. The results are shown in Figure 2.

[0138] The effects of endothelial cells (EVs) on the expression of inflammatory cytokines (IL-6 and IL-1β) in LPS-stimulated mouse macrophages were evaluated. The expression levels of IL-6 and IL-1β were determined using RNA extracted from LPS-stimulated mouse macrophages and analyzed by RT-qPCR.

[0139] The expression results of aging markers in Ras-induced aging human IMR90 cells were obtained by sensitizing Ras-induced aging human IMR90 cells with EV fractions or PBS prepared using sucrose density gradient ultracentrifugation from plants, fungi, and microalgae listed in Table 1, and the expression results of IL-6 and IL-1β in sensitized mouse macrophages stimulated with LPS are shown in the figure. Figures 2-1 to 2-21 .

[0140] In addition, the expression results of IL-6 or IL-1β in mouse macrophages sensitized with various concentrations of EV fractions or EV samples or PBS (control) obtained by sucrose density gradient ultracentrifugation or ultrafiltration and then stimulated with LPS are shown in the figure. Figures 3-1 to 3-2 Results of EV fractions or EV samples of various concentrations obtained by sucrose density gradient ultracentrifugation or ultrafiltration are shown in the figure. Figure 3-1 Results of EVs samples of various concentrations obtained by ultrafiltration (TFF) from parsley and ginger ale are shown in the figure. Figure 3-2 .

[0141] Figures 2-1 to 2-21 as well as Figure 3-1 and Figure 3-2 The expression results (vertical axis) use Gapdh as an internal reference gene and are expressed as a relative value (fold change) with the expression level in cells with PBS added instead of EV fractional solution or EV sample and stimulated with Ras or LPS as 1. Figure 3-2 The horizontal axis represents the EV concentration (particles / mL). Figures 2-1 to 2-21 The results showed that, compared with the addition of PBS, the expression of inflammatory cytokines was significantly reduced in mouse macrophages exposed to EV fractions derived from various plants, fungi, or microalgae shown in Table 1.

[0142] In addition, according to Figure 3-1 and Figure 3-2 The results showed that EVs derived from winged beans, parsley, and ginger from the grains dose-dependently inhibited the expression of inflammatory cytokines in mouse macrophages. EVs samples derived from winged beans, prepared by ultrafiltration, exhibited more potent inhibitory activity compared to EV fractions prepared by sucrose density gradient ultracentrifugation at the same dosage.

[0143] (1-8) Nanoparticle Tracking Analysis (NTA) The particle size, particle size distribution, and concentration of EVs were measured using a NanoSight NS300 or LM10 (Malvern Instruments) equipped with a 405nm blue laser in sucrose density gradient ultracentrifugation fractions derived from winged beans, parsley, ginger amaranth, and Euglena, as well as in EV samples derived from winged beans, parsley, and ginger amaranth obtained by ultrafiltration. Results for winged beans are shown below. Figure 4-1 The results for parsley are shown in Figure 4-2 The results of ginger in the valley are shown in Figure 4-3 In addition, the results for Euglena are shown in Figure 4-4 . Figure 4-1 A, Figure 4-2 A, Figure 4-3 A and Figure 4-4 A shows the results of EV fractionation solutions prepared by sucrose density gradient ultracentrifugation (UC). Figure 4-1 B Figure 4-2 B and Figure 4-3 B shows the results of EV samples prepared by ultrafiltration (TFF).

[0144] according to Figures 4-1 to 4-4 The results showed that the EV fractions prepared by sucrose density gradient ultracentrifugation from winged bean, parsley, ginger alfalfa, and Euglena contained EVs with average sizes of 128 nm (50–500 nm), 216 nm (50–500 nm), 215 nm (50–500 nm), and 211 nm (50–500 nm), respectively. Furthermore, the EV samples prepared by ultrafiltration from winged bean, parsley, and ginger alfalfa contained EVs with average sizes of 125 nm (50–300 nm), 148 nm (50–300 nm), and 135 nm (50–300 nm), respectively. Therefore, ultrafiltration can produce EVs with narrower sizes compared to sucrose density gradient ultracentrifugation.

[0145] <Example 2> (2) Improvement effect on human skin Freeze-dried parsley EVs were suspended in water, and 8 x 10 ml were taken orally before bedtime daily. 12 Particles / day, for 5 weeks. Afterwards, facial skin condition was analyzed using the VISIA skin imaging diagnostic device. Figure 5-1 and Figure 5-2 ). Figure 5-1The results showed that Parsley EVs significantly improved skin whitening, skin renewal, pores, uneven skin tone, pigmentation (age spots, melasma, inflammatory hyperpigmentation), hyperpigmentation, redness, dullness, rough skin texture, firmness, and sagging. Additionally, Figure 5-2 Measurements of melanin deep within the skin showed that the melanin causing pigmentation was metabolized and significantly reduced in size. Figure 5-2 (Left and middle figures) Compared with peers who underwent VISIA analysis, the results show the percentage of groups that increased from the bottom up ( Figure 5-2 (See right image). Therefore, parsley EVs significantly improved latent pigmentation (the precursors of pigmentation invisible to the naked eye). Thus, parsley EVs are considered to have skin-improving effects.

[0146] <Example 3> (3) Stability of EVs during heat treatment For the prepared EVs solution, after treatment under typical food-grade heat treatment conditions (65°C for 10 minutes or 85°C for 30 minutes), at 1×10 10 The IL-6 expression level was added to the culture medium in a particle / ml manner. After sensitizing mouse macrophages (Raw-Blue cells) for 16 hours, they were stimulated with 1 μg / ml LPS for 24 hours and then washed with PBS. RNA was then extracted using TRIsure, and cDNA was synthesized via reverse transcription. IL-6 expression was confirmed by qPCR. Cells with an equal volume of PBS added to the culture medium instead of EVs were used as a control. The relative value of IL-6 expression in the control cells was set as 1. Figure 6 ).

[0147] according to Figure 6 The results from -A show that even when EVs derived from plants (from parsley) were heated to 65°C and 85°C, their effectiveness was not diminished compared to unheated EVs. Furthermore, according to... Figure 6 The results from -B show that EVs derived from microalgae (Euglena) also exhibited no decrease in effectiveness compared to untreated EVs, even after heat treatment. Therefore, it can be concluded that EVs derived from parsley and microalgae possess heat resistance. Consequently, EVs derived from parsley and microalgae do not lose their activity due to heat treatment and can be easily sterilized for product manufacturing.

[0148] <Example 4> (4) Anti-inflammatory effect in mouse colitis model mice 10 once a day 11 One week after administration of parsley-derived EVs to wild-type 8-week-old male mice (C57BL / 6J), 3% sodium dextran sulfate (DSS) that causes colitis was added to the drinking water, followed by administration of an equal amount of parsley-derived EVs.

[0149] like Figure 7A As shown, in the phase without DSS treatment, the same weight gain was observed in the group of mice given parsley-derived EVs as in the PBS intake group used as a control, and no acute toxicity of parsley-derived EVs was found in individuals.

[0150] In addition, such as Figure 7B As shown, starting from day 3 of DSS ingestion, blood was found in the feces of both the PBS ingestion group and the parsley-derived EVs ingestion group, and the incidence increased with the number of days of administration. In the PBS ingestion group, 50% of mice showed anal bleeding on day 6 and 100% on day 7; in contrast, in the parsley-derived EVs ingestion group, 30% of mice showed anal bleeding on day 6 and 50% on day 7. The length of the large intestine from the cecum to the anus is shown in the figure. Figure 7C As shown, the PBS intake group showed a significant decrease after day 3, but the parsley-derived EVs intake group began to show significant differences after day 5.

[0151] Next, starting from the region near the cecum, the large intestine was divided into proximal (anterior), middle, and distal (posterior) regions. RNA was extracted, and changes in the expression of the inflammatory cytokine IL-6 were detected by qPCR. Figure 7D As shown, compared with the PBS ingestion group, the expression of EVs derived from parsley was significantly suppressed on day 7 of DSS ingestion.

[0152] In addition, after DSS ingestion, the tissue was perfused and fixed on days 0 and 7. Paraffin sections of the large intestine region from the cecum to the anus were prepared in the shape of a Swiss roll and stained with hematoxylin and eosin (HE) and alcian blue stain to observe the morphology of the large intestine sections. Figure 7E As shown, on day 0 of DSS intake, both the PBS intake group and the parsley-derived EVs intake group exhibited allicin blue staining regions with carboxyl and sulfate groups bound to acidic mucopolysaccharides, extending throughout the distal colon region. Figure 7E The area enclosed by the square in the left image covers almost the entire region. In contrast, in the PBS intake group on day 7 of DSS intake, the alcine blue staining area in the distal colon almost disappeared, while in the EVs intake group derived from parsley, the alcine blue staining area remained in the distal colon. Furthermore, in immunostaining images using the epithelial cell markers β-catenin and ZO-1, similarly, a significant loss of the monolayer cylindrical epithelial structure was observed in the PBS intake group on day 7 of DSS intake, while the epithelial structure was maintained in the EVs intake group derived from parsley.

[0153] <Example 5> (5) Treatment efficacy of dermatitis Abdominal hair was removed from 8-week-old male C57BL / 6J mice, and sensitization was achieved by applying 150 μl / mouse of 5% TNCB (2,4,6-trinitrochlorobenzene: Tokyo Chemical Industry) dissolved in acetone:ethanol (1:9). Six days later, 10 μl of 1% TNCB dissolved in acetone was applied to the surface and dorsal surface of both ears to induce inflammation. Acetone was applied to the uninduced inflammation group. Six hours after inflammation induction, mice were treated with PBS or 1.8 × 10⁻⁶ PBS. 10 10 μl solutions of EVs derived from Brussels sprouts and EVs derived from parsley were applied to the surface and back of both ears, respectively, and rubbed in with fingers to allow saturation. After 18 hours, the thickness of the auricle was measured using a micrometer. The results are shown below. Figure 8 A. Measurements were taken from both ears, and the average value was used as the auricle thickness for that individual. According to... Figure 8 The results showed that, compared with the control PBS group, the group that received EVs derived from Brussels sprouts or EVs derived from parsley significantly suppressed ear swelling accompanied by inflammation.

[0154] Next, after measuring ear thickness, RNA was recovered from the auricle of the left ear, and the expression levels of inflammatory cytokines were determined by RT-qPCR. The results are shown in... Figure 8 B.

[0155] <Example 6> (6) Evaluation of the effects of plant EVs on obese mice To quantitatively evaluate the effects of endothelial growth factors (EVs) derived from parsley or Brussels sprouts on aging and muscle weakness associated with obesity in mice, obese mice were induced to become obese by feeding them a high-fat diet for 13 weeks. Simultaneously, EVs derived from parsley and Brussels sprouts were administered via drinking water. Grip strength tests and 4-limb hanging tests were performed on non-obese mice (HFD-), obese mice (HFD+), and obese mice given EVs derived from parsley or Brussels sprouts. Additionally, the weight of the soleus muscle in each mouse was measured.

[0156] Specifically, 5-week-old C57B6J mice were obtained from Charles River and, after one week of acclimatization, were divided into three groups with equal average body weight. Each group was fed a high-fat diet for 13 weeks while simultaneously receiving 3×10 [units of a specific medication / treatment]. 9Pure water containing EVs derived from parsley and Brussels sprouts at a concentration of 1 / mL. Students were given free access to standard food D12450B (Research Diet) and high-fat food D12492 (Research Diet), respectively. The high-fat food and pure water containing the respective EVs were replaced twice weekly.

[0157] The grip strength test was performed on obese mice administered various EVs using a smart rat / mouse grip strength measuring device MK-380Si (Muromachi Machinery Manufacturing), measuring each mouse three times. The average value was taken as the grip strength value for each mouse. The results are shown below. Figure 9 .

[0158] In addition, the 4-limb Hanging Test was conducted using a wire hanging test chamber (manufactured by Ohara Medical Sangyo Co., Ltd.). With all four limbs of the mouse gripping a metal mesh, the mesh and the mouse were rotated up and down together. The time the mouse could tolerate before falling was recorded as the hanging time, and this endurance time was multiplied by the mouse's weight to obtain the hanging score. The results are shown in... Figure 10 .

[0159] Soleus muscle was recovered from the hind limbs of mice fed a high-fat diet and various EVs for 13 weeks, and its weight was measured and evaluated. The results are shown in... Figure 11 .

[0160] In the grip strength test, it was found that obesity accompanied by a high-fat diet load led to a decrease in grip strength in the high-fat diet administration group. However, compared with the control obese mouse group, the mouse group administered EVs derived from parsley and Brussels sprouts showed high grip strength values. Figure 9 Additionally, in the 4-limb Hanging Test, obesity was found to increase the endurance time in the inverted position (hanging time). Figure 10 -A) and the score obtained by multiplying endurance time by the mouse's body weight (Hanging score) Figure 10 -C) decreased, however, compared with the control obese mouse group, the suspension time of the obese mouse group administered EVs derived from Brussels sprouts was ( Figure 10 -B), Hanging Score ( Figure 10The -D values ​​were significantly larger, indicating that obese mice treated with EVs derived from Brussels sprouts had high muscle endurance. No significant differences were found in the 4-limb hanging test in obese mice treated with EVs derived from parsley; however, they showed a tendency to inhibit the decline in muscle endurance. Figure 10 -B、D).

[0161] Furthermore, when the soleus muscle was isolated from the hind limbs of each mouse and its weight was measured, the soleus muscle weight was significantly increased in obese mice treated with EVs derived from parsley and Brussels sprouts compared with the control obese mouse group. Figure 11 ).

[0162] As mentioned above, EVs derived from parsley and Brussels sprouts have the effect of inhibiting the decline in muscle strength and endurance, that is, they have an anti-aging effect.

Claims

1. A composition for anti-inflammatory or anti-aging purposes, wherein, It contains extracellular vesicles from plants, fungi, or microalgae originating from the Apiaceae, Lamiaceae, Theaceae, Selaginellaceae, Brassicaceae, Asteraceae, Amaranthaceae, Amaryllidaceae, Fabaceae, Cucurbitaceae, Zingiberaceae, Polygonaceae, Dioscoreaceae, Vitaceae, Rosaceae, Solanaceae, Ericaceae, Lythraceae, or Rutaceae families.

2. A composition for anti-inflammatory or anti-aging purposes, wherein, Contains ingredients derived from parsley, Ashitaba, clover, purple carrot, carrot, carrot tops, fruit carrot, coriander, dill, fennel, rosemary, spearmint, lemon balm, perilla, marjoram, sweet basil, thyme, oregano, mint, sage, tea tree, camellia, selaginella, Brussels sprouts, Japanese cauliflower, Romanesco broccoli, arugula, horseradish, komatsuna, wasabi, cauliflower, red radish, thin-leaf mustard, bok choy, broccoli, mizuna, small radish, white radish, watercress, turnip, tatsoi, and Korean cabbage. Thistle, goldenrod, garland chrysanthemum, lettuce, burdock, chicory, Jerusalem artichoke, romaine lettuce, red chicory, wild mustard, amaranth, spinach, Swiss chard, beetroot, wingless hogweed, leek, scallion, onion, green onion, Moroccan green bean, edamame, winged bean, snow pea, sweet bean, pea sprout, watermelon, zucchini, loofah, ginger, ginger, rhubarb, yam, muscat grape, mulberry, bell pepper, chili pepper, potato, green bell pepper, blueberry, pomegranate, Thai lemon, kumquat, button mushroom, shiitake mushroom, crab mushroom, or extracellular vesicles of Euglena.

3. The composition of claim 1 or 2, which inhibits the expression of inflammatory cytokines or aging markers.

4. The composition of claim 3, wherein, Inflammatory cytokines or aging markers include IL-4, IL-6, IL-13, IL-33, IL-1β, CXCL1, CXCL2, TNF-α, p15, or p16.

5. The composition according to claim 1 or 2, wherein, It is used in food, cosmetics, or medicine.

6. A composition for anti-inflammatory or anti-aging purposes, wherein, It contains extracellular vesicles derived from parsley or Euglena.

7. The composition of claim 6, wherein, The anti-inflammatory or anti-aging effects are not diminished by the thermal process.

8. The composition of claim 7, wherein, The thermal process involves heating at temperatures above 40°C.

Citation Information

Patent Citations

  • Composition for improving skin and preventing hair loss containing extracellular endoplasmic reticulum derived from plant juice

    JP2018531932A

  • Composition containing plant-derived extracellular endoplasmic reticulum

    JP2020535189A

  • Viral infection improving agent comprising exosome derived from eucommia leaf

    JP2021193070A

  • Plant-derived extracellular vesicle (EV) compositions and uses thereof

    JP2022525131A

  • Plant exosomes used to treat diseases caused by protein aggregates formed within cells

    JP2022543061A